Bristol-Myers Squibb’s Repotrectinib DDI Study: What Investors Should Watch

Bristol-Myers Squibb Company (BMY) announced an update on their ongoing clinical study.

The Phase 1 study “Phase 1, 2-Cohort, Open-label, Fixed-sequence, Drug-drug Interaction Study to Evaluate the Effect of Repotrectinib on the Pharmacokinetics of Transporter and CYP P450 Probe Substrates in Healthy Adult Participants” tests how Bristol-Myers Squibb’s cancer drug repotrectinib affects levels of several common drugs. It helps investors gauge how clean the drug’s interaction profile may be and how easily it could be used in real world patients.

The trial gives repotrectinib together with well known medicines such as metformin, digoxin, rosuvastatin, bupropion, flurbiprofen, and omeprazole. These partner drugs act as probes to show whether repotrectinib raises or lowers their blood levels, which in turn signals how it may interact with other treatments in the clinic.

The study is interventional, meaning participants receive active drugs under controlled conditions. It uses a non random design with parallel groups, is open label with no blinding, and is labeled as treatment focused, but the main aim is to map drug interactions rather than to treat disease.

The study began after its first submission on October 30, 2025, marking the formal start of regulatory tracking. It reached its primary completion before the latest update and is now listed as completed, with the record most recently updated on March 24, 2026, signaling fresh information for investors.

For BMY, a clean interaction profile for repotrectinib would support broader use, simpler labeling, and smoother uptake in oncology practice. Any signals of complex drug interactions could slow adoption or require label warnings, but they are unlikely to derail the asset unless safety issues are severe.

Competitors in targeted oncology, including large pharma and smaller biotechs, face the same scrutiny on drug interactions. If repotrectinib shows fewer practical dosing limits than rival agents, BMY could gain a commercial edge and support a stronger narrative for its precision oncology pipeline.

Investors should watch for how future labels or presentations describe interaction data rather than the study mechanics themselves. Clear guidance that repotrectinib can be used safely with common treatments such as diabetes, heart, and stomach acid drugs would support confidence in long term revenue contribution.

The trial is now completed and recently updated, and full details and any emerging results will be available on the ClinicalTrials portal as they are posted.

To learn more about BMY’s potential, visit the Bristol-Myers Squibb Company drug pipeline page.